Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Evoke Pharma Inc.
Fiscal year is January-December. All values USD millions. 2011 2012 2013 5-year trend
Sales/Revenue - - 0 0 0
Cost of Goods Sold (COGS) incl. D&A - - 0 0 0
COGS excluding D&A - - 0 0 0
Depreciation & Amortization Expense - - 0 0 0
Depreciation - - 0 0 0
Amortization of Intangibles - - 0 0 0
Gross Income - - 0 0 0
2011 2012 2013 5-year trend
SG&A Expense - - 2.41M 2M 2.6M
Research & Development - - 1.84M 1.17M 956,980
Other SG&A - - 570,524 836,781 1.64M
Other Operating Expense - - 0 0 0
Unusual Expense - - (5,500) (7,250) 82,000
EBIT after Unusual Expense - - 5,500 7,250 (82,000)
Non Operating Income/Expense - - 0 0 0
Non-Operating Interest Income - - 10,696 1,690 7,248
Equity in Affiliates (Pretax) - - 0 0 0
Interest Expense - - 2,872 24,042 159,885
Gross Interest Expense - - 2,872 24,042 159,885
Interest Capitalized - - 0 0 0
Pretax Income - - (2.4M) (2.02M) (2.84M)
Income Tax - - 0 0 0
Income Tax - Current Domestic - - 0 0 -
Income Tax - Current Foreign - - 0 0 -
Income Tax - Deferred Domestic - - 0 0 -
Income Tax - Deferred Foreign - - 0 0 -
Income Tax Credits - - 0 0 -
Equity in Affiliates - - 0 0 0
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income - - (2.4M) (2.02M) (2.84M)
Minority Interest Expense - - 0 0 0
Net Income - - (2.4M) (2.02M) (2.84M)
Extraordinaries & Discontinued Operations - - 0 0 0
Extra Items & Gain/Loss Sale Of Assets - - 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations - - 0 0 0
Net Income After Extraordinaries - - (2.4M) (2.02M) (2.84M)
Preferred Dividends - - 0 0 0
Net Income Available to Common - - (2.4M) (2.02M) (2.84M)
EPS (Basic) - - (0.67) (0.57) (1.20)
Basic Shares Outstanding - - 3.56M 3.56M 2.37M
EPS (Diluted) - - (0.67) (0.57) (1.20)
Diluted Shares Outstanding - - 3.56M 3.56M 2.37M
EBITDA - - (2.41M) (2M) (2.6M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.